SlideShare a Scribd company logo
M. Reza Sailani, PhD
Department of Genetics
Stanford University
http://snyderlab.stanford.edu/index.html
sailani@stanford.edu
Genetic Determinants of Rare Diseases
• Introduction
• Our Current state of research
• An overview of two whole exome sequencing studies of mendelian diseases.
Case#1: Alopecia and Mental Retardation (APMR) Syndrome
Case#2: Pseudorheumatoid Dysplasia
• Concluding remarks
http://snyderlab.stanford.edu/index.html
Current Research:
Our laboratory develops and uses a variety of approaches to analyze genomes, other
omes, and regulatory networks. We apply these approaches to understand human
variation and health.
Genetic Determinants Of Rare And Complex Diseases:
Type 2 diabetes
Familial Tremor
Alopecia and Mental Retardation
Pseudorheumatoid Dysplasia
Isolated Congenital Anosmia
Deafness and infertility syndrome
Epilepsy
Leukodystrophies
Intellectual Disability
Hydroxyurea treatment responses in beta-thalassemia patients
Case #1
Alopecia And Mental Retardation (APMR) Syndrome
• A very rare autosomal recessive condition
• Only a few families have been reported; most in the context of consanguinity.
• Affected individuals manifest with loss of hair on the scalp, the absence of eyebrows and
eyelashes, and variable intellectual disability.
• However, there is high genetic heterogeneity in APMR cases as none of the families
reported before shared the same aberrant locus associated with the disease.
• Linkage analyses in the past have identified three regions that are associated with APMR.
3q26.3-q27.3 (chr3:170,900,000-187,900,000)
17Mbp region
Alopecia-mental retardation syndrome 1 (APMR1)
Alopecia-mental retardation syndrome candidate regions: Linkage Analyses
APMR2, on chromosome 3q26.2-q26.31
chr3:167,600,001-175,700,000
APMR3, Chr18: 18q11.2-q12.2
Alopecia-mental retardation syndrome candidate regions: Linkage Analyses
Chr8: 8p22–p21.3
Chr14:14q24.3–q31.3
Chr1:1p31.1–p22.3
Alopecia And Mental Retardation (APMR) Syndrome
These previous studies were based on linkage analyses and were able to identify
regions of interest, but no specific causative genes or variants.
We employed whole-exome sequencing to identify the underlying genetic variant(s)
associated with APMR syndrome in a large consanguineous family.
Methods:
Capture Kit: Agilent SureSelectXT HumanAllExon V5
Four libraries per one lane of HiSeq2500
Hugeseq and BINA pipeline
VarSeq for variant filtering
HugeSeq
Fastq files
VarSeq
BWA mapping
BAM generation
Re-aligned around indels with GATK IndelRealigner.
base recalibration by GATK BaseRecalibrator
Duplicate removal
Local realignment
Calling variants by GATK HaplotypeCaller
VQSR was used to recalibrate the variantsVCF files
Pedigree files
Disease model filtering:
Autosomal Recessive
Autosomal Dominant
DeNovo
X-linked
SNP frequency filtering (1000g,dpSNPs,etc )
Pathogenesity filtering (Non_synanmous/Frameshift)
Final list of
variants
(Snyder lab, Nature Biotech 2012)
Variant Calling Pipeline
We selected variants with minor allele frequency (MAF) less than 0.01 in public databases:
• dbSNP Common 144 (Database of Single Nucleotide Polymorphism, NCBI).
• 1000 Genome project phase 3 (http://www.1000genomes.org).
• Exome Aggregation Consortium (ExAC).
• Exome Variant Server-NHLBI GO Exome Sequencing Project (ESP), Seattle, WA
(http://evs.gs.washington.edu/EVS/).
VarSeq filtering Steps:
As an autosomal recessive mode of inheritance is indicated both by the pattern of
segregation of APMR syndrome in this family and in previous reported families, we began
by searching for homozygous variants.
VarSeq filtering Steps:
VarSeq filtering Steps:
Variant filtering steps using VarSeq software
MAF minor allele frequency. 1 kg, 1000 Genome project phase 3,. EXaC, Exome
Aggregation Consortium version 0.3. dbSNP 144, Database of Single Nucleotide
Polymorphism, NCBI. NHLBI, Exome Variant Server; NHLBI GO Exome Sequencing
Project (ESP)
The identified variant (rs201849460) is rare, predicted to be
deleterious and falls within exon 7 of AHSG gene.
(MAF 0.0008% in EXaC, 0.04% in dbSNP 144; no homozygotes)
rs201849460
Runs of Homozygosity and AHSG location on chromosome 3.
ROH are long stretches of consecutive homozygous genotypes reflecting segments shared identically
by descent (Broman and Weber 1999) and known to harbor mutations for recessive diseases.
ROH were estimated by H3M2 algorithm (Magi et al. 2014).
AHSG resides within a 17 Mb linkage region previously reported to be associated with
APMR (APMR1)
3q26.3-q27.3 (chr3:170,900,000-187,900,000)
17Mbp region
Alopecia-mental retardation syndrome 1 (APMR1)
The amino acid sequence of AHSG colored according to the conservation scores.
p.Arg317His occurs in a predicted functional residue, highly conserved and exposed
(generated by ConSurf method).
We confirmed the homozygosity of this variant by Sanger sequencing
Post-translational modifications (PTMs) are common in AHSG protein
The identified variant is predicted to affect the pro-peptide
Immune-precipitating AHSG from serum followed
by SDS polyacrylamide gel electrophoresis
Arg317His disrupts a phosphorylation motif
We used MIMP algorithm to evaluate the potential impact of p.Arg317His on this motif.
p.Arg317His disrupts this phosphorylation
motif, potentially leading to a loss of
phosphorylation at p.Thr319.
• AHSG as a phosphorylated glycoprotein is a multifunctional extracellular calcium-
regulatory protein.
• Is an important participant of diverse normal and pathological processes, including
production of growth hormone (GH), nerve growth factor (NGF), transforming growth
factor II (TGFb).
• Promotes primary keratinocyte migration.
• Is particularly abundant at sites where basal keratinocytes are reorganizing to form hair
follicle placodes.
We therefore suggest AHSG gene as a potential
Candidate for APMR in this family.
WISP3 mutation associated with Pseudorheumatoid Dysplasia
Case #2
Here we report genetic characterization of a family segregating an uncharacterized
from of skeletal dysplasia.
The patients were asymptomatic at birth, with normal growth, development and
intelligence as well as no facial, joint, and skeletal system deformity. However, the disease
started to manifest at four to six years of age in affected individuals and progressively
worsened.
HugeSeq
Fastq files
VarSeq
BWA mapping
BAM generation
Re-aligned around indels with GATK IndelRealigner.
base recalibration by GATK BaseRecalibrator
Duplicate removal
Local realignment
Calling variants by GATK HaplotypeCaller
VQSR was used to recalibrate the variantsVCF files
Pedigree files
Disease model filtering:
Autosomal Recessive
Autosomal Dominant
DeNovo
X-linked
SNP frequency filtering (1000g,dpSNPs,etc )
Pathogenesity filtering (Non_synanmous/Frameshift)
Final list of
variants
(Snyder lab, Nature Biotech 2012)
Variant Calling Pipeline
We selected variants with minor allele frequency (MAF) less than 0.01 in public databases:
• dbSNP Common 144 (Database of Single Nucleotide Polymorphism, NCBI),
• 1000 Genome project phase 3 (http://www.1000genomes.org),
• Exome Aggregation Consortium version (ExAC)
• Exome Variant Server-NHLBI GO Exome Sequencing Project (ESP), Seattle, WA
(http://evs.gs.washington.edu/EVS/),
VarSeq filtering Steps:
As an autosomal recessive mode of inheritance is indicated by the pattern of segregation
of disease in this family, we began by searching for homozygous variants.
MAF minor allele frequency. 1 kg, 1000 Genome project phase 3,. EXaC, Exome Aggregation Consortium version 0.3. dbSNP 144, Database of Single
Nucleotide Polymorphism, NCBI. NHLBI, Exome Variant Server; NHLBI GO Exome Sequencing Project (ESP)
Our study is the first to report a homozygote loss of function mutation for
rs121908901; WISP3;c.210C>A; p.Cys70*.
VarSeq filtering Steps:
rs121908901
We confirmed the homozygosity of this variant by Sanger sequencing and showed that
the variant segregates in the family
Loss-of-function mutations in the WISP3 gene has been associated with Progressive
pseudorheumatoid dysplasia (PPD)
In 1998, linkage studies in consanguineous families segregating PPD (El-Shanti et al, 1998;
Fischer, J. et al 1998) mapped the candidate region on a 3-cM interval on chromosome
6q22.
One year later, Hurvitz et al 1999 showed that mutations in the WISP3 gene that fall within
the linkage region are the strongest candidate to cause this autosomal recessive condition
(Hurvitz et al 1999).
Progressive pseudorheumatoid dysplasia (PPD):
A rare skeletal dysplasia characterized by predominant involvement of articular cartilage
with progressive joint stiffness.
is an autosomal recessive genetic disease.
PPD remains a diagnostic challenge because of the rarity
of the disease and the heterogeneity in the phenotypes,
as well as having similarities with other disorders.
Clinical and radiographic findings in a 13-year-old
male PPD patient
Nature Genetics 23, 94 - 98 (1999)
PPD is caused by Wnt1-inducible signaling
protein 3 (WISP3) mutations.
WISP3 encodes Wnt1-inducible signaling protein 3, a cysteine-rich,
multidomain, secreted protein
WISP3:c.210C>A p.Cys70* occurs in IGFBP N-terminal domain
The variant identified in this study at p.Cys70* would, if not subjected to nonsense mediated
mRNA decay, produce a significantly truncated protein that misses major part of the protein
making it unlikely that normal protein function would be retained.
Combining our whole exome sequencing data with clinical documentation (familial
histories, genetic data, clinical and radiological findings), we have diagnosed the families
with Progressive Pseudorheumatoid Dysplasia (PPD).
Conclusion:

More Related Content

What's hot

Applications of Gene Editing: CRISPR-Cas9 in Cancer Therapeutics (Oncogenes)
Applications of Gene Editing: CRISPR-Cas9 in Cancer Therapeutics (Oncogenes)Applications of Gene Editing: CRISPR-Cas9 in Cancer Therapeutics (Oncogenes)
Applications of Gene Editing: CRISPR-Cas9 in Cancer Therapeutics (Oncogenes)
Alaakhamis0325098
 
Cell cycle , genotoxic stess cancer
Cell cycle , genotoxic stess  cancerCell cycle , genotoxic stess  cancer
Cell cycle , genotoxic stess cancer
ABHISHEK MITRA
 
Cell cycle , genotoxic stress cancer
Cell cycle , genotoxic stress  cancerCell cycle , genotoxic stress  cancer
Cell cycle , genotoxic stress cancer
Sudheer998
 
Embed Repro Test
Embed Repro TestEmbed Repro Test
Embed Repro Test
askreprogenetics
 
MicroarrayAnalysisinR_2014
MicroarrayAnalysisinR_2014MicroarrayAnalysisinR_2014
MicroarrayAnalysisinR_2014
Boshika Tara
 
Human Genome
Human GenomeHuman Genome
Human Genome
Adonis Sfera, MD
 
Comparative analysis of gene regulation in mouse rat and human
Comparative analysis of gene regulation in mouse rat and humanComparative analysis of gene regulation in mouse rat and human
Comparative analysis of gene regulation in mouse rat and human
constantina mylona
 
Fs Ch 14
Fs Ch 14Fs Ch 14
Fs Ch 14
warren142
 
Single nucleotide polymorphism
Single nucleotide polymorphismSingle nucleotide polymorphism
Single nucleotide polymorphism
Bipul Das
 
Newborn genetic screening for high risk deafness associated 2
Newborn genetic screening for high risk deafness associated 2Newborn genetic screening for high risk deafness associated 2
Newborn genetic screening for high risk deafness associated 2
Dr. Satyender Kumar
 
20160218 hisham toma services
20160218 hisham toma services20160218 hisham toma services
20160218 hisham toma services
ToMa Advanced Biomedical Assays Spa
 
Lrrk2 nww-wood
Lrrk2 nww-woodLrrk2 nww-wood
Lrrk2 nww-wood
Conferences
 
ResearchreportSTS
ResearchreportSTSResearchreportSTS
ResearchreportSTS
Apostolos Katsiaunis
 
J. Martin, SUR Programme
J. Martin, SUR ProgrammeJ. Martin, SUR Programme
J. Martin, SUR Programme
Johanna Martin
 
Platelet Endo Meeting Feb2009
Platelet Endo Meeting Feb2009Platelet Endo Meeting Feb2009
Platelet Endo Meeting Feb2009
guest7d5b8c
 
ARVO 2007 Developmental Biology Program
ARVO 2007 Developmental Biology ProgramARVO 2007 Developmental Biology Program
ARVO 2007 Developmental Biology Program
Kim Paes
 
Gene therapy.. Dr.Padmesh
Gene therapy..  Dr.PadmeshGene therapy..  Dr.Padmesh
Gene therapy.. Dr.Padmesh
Dr Padmesh Vadakepat
 
Detection of genetic disease
Detection of genetic diseaseDetection of genetic disease
Detection of genetic disease
shah faisal
 

What's hot (18)

Applications of Gene Editing: CRISPR-Cas9 in Cancer Therapeutics (Oncogenes)
Applications of Gene Editing: CRISPR-Cas9 in Cancer Therapeutics (Oncogenes)Applications of Gene Editing: CRISPR-Cas9 in Cancer Therapeutics (Oncogenes)
Applications of Gene Editing: CRISPR-Cas9 in Cancer Therapeutics (Oncogenes)
 
Cell cycle , genotoxic stess cancer
Cell cycle , genotoxic stess  cancerCell cycle , genotoxic stess  cancer
Cell cycle , genotoxic stess cancer
 
Cell cycle , genotoxic stress cancer
Cell cycle , genotoxic stress  cancerCell cycle , genotoxic stress  cancer
Cell cycle , genotoxic stress cancer
 
Embed Repro Test
Embed Repro TestEmbed Repro Test
Embed Repro Test
 
MicroarrayAnalysisinR_2014
MicroarrayAnalysisinR_2014MicroarrayAnalysisinR_2014
MicroarrayAnalysisinR_2014
 
Human Genome
Human GenomeHuman Genome
Human Genome
 
Comparative analysis of gene regulation in mouse rat and human
Comparative analysis of gene regulation in mouse rat and humanComparative analysis of gene regulation in mouse rat and human
Comparative analysis of gene regulation in mouse rat and human
 
Fs Ch 14
Fs Ch 14Fs Ch 14
Fs Ch 14
 
Single nucleotide polymorphism
Single nucleotide polymorphismSingle nucleotide polymorphism
Single nucleotide polymorphism
 
Newborn genetic screening for high risk deafness associated 2
Newborn genetic screening for high risk deafness associated 2Newborn genetic screening for high risk deafness associated 2
Newborn genetic screening for high risk deafness associated 2
 
20160218 hisham toma services
20160218 hisham toma services20160218 hisham toma services
20160218 hisham toma services
 
Lrrk2 nww-wood
Lrrk2 nww-woodLrrk2 nww-wood
Lrrk2 nww-wood
 
ResearchreportSTS
ResearchreportSTSResearchreportSTS
ResearchreportSTS
 
J. Martin, SUR Programme
J. Martin, SUR ProgrammeJ. Martin, SUR Programme
J. Martin, SUR Programme
 
Platelet Endo Meeting Feb2009
Platelet Endo Meeting Feb2009Platelet Endo Meeting Feb2009
Platelet Endo Meeting Feb2009
 
ARVO 2007 Developmental Biology Program
ARVO 2007 Developmental Biology ProgramARVO 2007 Developmental Biology Program
ARVO 2007 Developmental Biology Program
 
Gene therapy.. Dr.Padmesh
Gene therapy..  Dr.PadmeshGene therapy..  Dr.Padmesh
Gene therapy.. Dr.Padmesh
 
Detection of genetic disease
Detection of genetic diseaseDetection of genetic disease
Detection of genetic disease
 

Similar to Whole Exome Sequencing at Stanford University

A New Generation Of Mechanism-Based Biomarkers For The Clinic
A New Generation Of Mechanism-Based Biomarkers For The ClinicA New Generation Of Mechanism-Based Biomarkers For The Clinic
A New Generation Of Mechanism-Based Biomarkers For The Clinic
Joaquin Dopazo
 
Supporting Genomics in the Practice of Medicine by Heidi Rehm
Supporting Genomics in the Practice of Medicine by Heidi RehmSupporting Genomics in the Practice of Medicine by Heidi Rehm
Supporting Genomics in the Practice of Medicine by Heidi Rehm
Knome_Inc
 
Towards Precision Medicine: Tute Genomics, a cloud-based application for anal...
Towards Precision Medicine: Tute Genomics, a cloud-based application for anal...Towards Precision Medicine: Tute Genomics, a cloud-based application for anal...
Towards Precision Medicine: Tute Genomics, a cloud-based application for anal...
Reid Robison
 
From reads to pathways for efficient disease gene finding
From reads to pathways for efficient disease gene findingFrom reads to pathways for efficient disease gene finding
From reads to pathways for efficient disease gene finding
Joaquin Dopazo
 
cytogenomics tools and techniques and chromosome sorting.pptx
cytogenomics tools and techniques and chromosome sorting.pptxcytogenomics tools and techniques and chromosome sorting.pptx
cytogenomics tools and techniques and chromosome sorting.pptx
PABOLU TEJASREE
 
Aug2013 Heidi Rehm integrating large scale sequencing into clinical practice
Aug2013 Heidi Rehm integrating large scale sequencing into clinical practiceAug2013 Heidi Rehm integrating large scale sequencing into clinical practice
Aug2013 Heidi Rehm integrating large scale sequencing into clinical practice
GenomeInABottle
 
12.Screening
12.Screening12.Screening
12.Screening
ghalan
 
Arjun's Poster ACTUAL FINAL POSTER
Arjun's Poster ACTUAL FINAL POSTERArjun's Poster ACTUAL FINAL POSTER
Arjun's Poster ACTUAL FINAL POSTER
Arjun Mahadevan
 
DOOR syndrome
DOOR syndromeDOOR syndrome
DOOR syndrome
Satrupa Das
 
gene mapping, clonning of disease gene(1).pptx
gene mapping, clonning of disease gene(1).pptxgene mapping, clonning of disease gene(1).pptx
gene mapping, clonning of disease gene(1).pptx
Rajesh Yadav
 
Genetics in Psychiatry
Genetics in PsychiatryGenetics in Psychiatry
Genetics in Psychiatry
Dr. Sriram Raghavendran
 
Molecular marker
Molecular markerMolecular marker
Molecular marker
adeelafaisal
 
Genomics Technologies
Genomics TechnologiesGenomics Technologies
Genomics Technologies
Sean Davis
 
Next Generation Sequencing and its Applications in Medical Research - Frances...
Next Generation Sequencing and its Applications in Medical Research - Frances...Next Generation Sequencing and its Applications in Medical Research - Frances...
Next Generation Sequencing and its Applications in Medical Research - Frances...
Sri Ambati
 
Molecular markers by tahura mariyam ansari
Molecular markers by tahura mariyam ansariMolecular markers by tahura mariyam ansari
Molecular markers by tahura mariyam ansari
Tahura Mariyam Ansari
 
LAMB3(2014)
LAMB3(2014)LAMB3(2014)
LAMB3(2014)
Walid Elsayed
 
Секвенирование как инструмент исследования сложных фенотипов человека: от ген...
Секвенирование как инструмент исследования сложных фенотипов человека: от ген...Секвенирование как инструмент исследования сложных фенотипов человека: от ген...
Секвенирование как инструмент исследования сложных фенотипов человека: от ген...
BioinformaticsInstitute
 
MLGG_for_linkedIn
MLGG_for_linkedInMLGG_for_linkedIn
MLGG_for_linkedIn
Manuel Gonzalez-Garay
 
Molecular techniques for pathology research - MDX .pdf
Molecular techniques for pathology research - MDX .pdfMolecular techniques for pathology research - MDX .pdf
Molecular techniques for pathology research - MDX .pdf
sabyabby
 
Open Source Pharma /Genomics and clinical practice / Prof Hosur
Open Source Pharma /Genomics and clinical practice / Prof Hosur Open Source Pharma /Genomics and clinical practice / Prof Hosur
Open Source Pharma /Genomics and clinical practice / Prof Hosur
opensourcepharmafound
 

Similar to Whole Exome Sequencing at Stanford University (20)

A New Generation Of Mechanism-Based Biomarkers For The Clinic
A New Generation Of Mechanism-Based Biomarkers For The ClinicA New Generation Of Mechanism-Based Biomarkers For The Clinic
A New Generation Of Mechanism-Based Biomarkers For The Clinic
 
Supporting Genomics in the Practice of Medicine by Heidi Rehm
Supporting Genomics in the Practice of Medicine by Heidi RehmSupporting Genomics in the Practice of Medicine by Heidi Rehm
Supporting Genomics in the Practice of Medicine by Heidi Rehm
 
Towards Precision Medicine: Tute Genomics, a cloud-based application for anal...
Towards Precision Medicine: Tute Genomics, a cloud-based application for anal...Towards Precision Medicine: Tute Genomics, a cloud-based application for anal...
Towards Precision Medicine: Tute Genomics, a cloud-based application for anal...
 
From reads to pathways for efficient disease gene finding
From reads to pathways for efficient disease gene findingFrom reads to pathways for efficient disease gene finding
From reads to pathways for efficient disease gene finding
 
cytogenomics tools and techniques and chromosome sorting.pptx
cytogenomics tools and techniques and chromosome sorting.pptxcytogenomics tools and techniques and chromosome sorting.pptx
cytogenomics tools and techniques and chromosome sorting.pptx
 
Aug2013 Heidi Rehm integrating large scale sequencing into clinical practice
Aug2013 Heidi Rehm integrating large scale sequencing into clinical practiceAug2013 Heidi Rehm integrating large scale sequencing into clinical practice
Aug2013 Heidi Rehm integrating large scale sequencing into clinical practice
 
12.Screening
12.Screening12.Screening
12.Screening
 
Arjun's Poster ACTUAL FINAL POSTER
Arjun's Poster ACTUAL FINAL POSTERArjun's Poster ACTUAL FINAL POSTER
Arjun's Poster ACTUAL FINAL POSTER
 
DOOR syndrome
DOOR syndromeDOOR syndrome
DOOR syndrome
 
gene mapping, clonning of disease gene(1).pptx
gene mapping, clonning of disease gene(1).pptxgene mapping, clonning of disease gene(1).pptx
gene mapping, clonning of disease gene(1).pptx
 
Genetics in Psychiatry
Genetics in PsychiatryGenetics in Psychiatry
Genetics in Psychiatry
 
Molecular marker
Molecular markerMolecular marker
Molecular marker
 
Genomics Technologies
Genomics TechnologiesGenomics Technologies
Genomics Technologies
 
Next Generation Sequencing and its Applications in Medical Research - Frances...
Next Generation Sequencing and its Applications in Medical Research - Frances...Next Generation Sequencing and its Applications in Medical Research - Frances...
Next Generation Sequencing and its Applications in Medical Research - Frances...
 
Molecular markers by tahura mariyam ansari
Molecular markers by tahura mariyam ansariMolecular markers by tahura mariyam ansari
Molecular markers by tahura mariyam ansari
 
LAMB3(2014)
LAMB3(2014)LAMB3(2014)
LAMB3(2014)
 
Секвенирование как инструмент исследования сложных фенотипов человека: от ген...
Секвенирование как инструмент исследования сложных фенотипов человека: от ген...Секвенирование как инструмент исследования сложных фенотипов человека: от ген...
Секвенирование как инструмент исследования сложных фенотипов человека: от ген...
 
MLGG_for_linkedIn
MLGG_for_linkedInMLGG_for_linkedIn
MLGG_for_linkedIn
 
Molecular techniques for pathology research - MDX .pdf
Molecular techniques for pathology research - MDX .pdfMolecular techniques for pathology research - MDX .pdf
Molecular techniques for pathology research - MDX .pdf
 
Open Source Pharma /Genomics and clinical practice / Prof Hosur
Open Source Pharma /Genomics and clinical practice / Prof Hosur Open Source Pharma /Genomics and clinical practice / Prof Hosur
Open Source Pharma /Genomics and clinical practice / Prof Hosur
 

More from Golden Helix

Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionIntroducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European Union
Golden Helix
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
Golden Helix
 
Introducing VSPGx: Pharmacogenomics Testing in VarSeq
Introducing VSPGx: Pharmacogenomics Testing in VarSeqIntroducing VSPGx: Pharmacogenomics Testing in VarSeq
Introducing VSPGx: Pharmacogenomics Testing in VarSeq
Golden Helix
 
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
Golden Helix
 
From Panels to Genomes with VarSeq: The Complete Tertiary Platform for Short ...
From Panels to Genomes with VarSeq: The Complete Tertiary Platform for Short ...From Panels to Genomes with VarSeq: The Complete Tertiary Platform for Short ...
From Panels to Genomes with VarSeq: The Complete Tertiary Platform for Short ...
Golden Helix
 
Enhance Genomic Research with Polygenic Risk Score Calculations in SVS
Enhance Genomic Research with Polygenic Risk Score Calculations in SVSEnhance Genomic Research with Polygenic Risk Score Calculations in SVS
Enhance Genomic Research with Polygenic Risk Score Calculations in SVS
Golden Helix
 
VarSeq 2.5.0: VSClinical AMP Workflow from the User Perspective
VarSeq 2.5.0: VSClinical AMP Workflow from the User PerspectiveVarSeq 2.5.0: VSClinical AMP Workflow from the User Perspective
VarSeq 2.5.0: VSClinical AMP Workflow from the User Perspective
Golden Helix
 
VarSeq 2.5.0: Empowering Family Planning through Carrier Screening Analysis
VarSeq 2.5.0: Empowering Family Planning through Carrier Screening AnalysisVarSeq 2.5.0: Empowering Family Planning through Carrier Screening Analysis
VarSeq 2.5.0: Empowering Family Planning through Carrier Screening Analysis
Golden Helix
 
Identifying Oncogenic Variants in VarSeq
Identifying Oncogenic Variants in VarSeqIdentifying Oncogenic Variants in VarSeq
Identifying Oncogenic Variants in VarSeq
Golden Helix
 
Best Practices for Validating a Next-Gen Sequencing Workflow
Best Practices for Validating a Next-Gen Sequencing WorkflowBest Practices for Validating a Next-Gen Sequencing Workflow
Best Practices for Validating a Next-Gen Sequencing Workflow
Golden Helix
 
2023 Innovation Awards Winner, Dr. Muthukumaran
2023 Innovation Awards Winner, Dr. Muthukumaran2023 Innovation Awards Winner, Dr. Muthukumaran
2023 Innovation Awards Winner, Dr. Muthukumaran
Golden Helix
 
VarSeq 2.4.0: VSClinical ACMG Workflow from the User Perspective
VarSeq 2.4.0: VSClinical ACMG Workflow from the User PerspectiveVarSeq 2.4.0: VSClinical ACMG Workflow from the User Perspective
VarSeq 2.4.0: VSClinical ACMG Workflow from the User Perspective
Golden Helix
 
VarSeq 2.4.0: Structural Variants and Advanced Automation in VSClinical ACMG
VarSeq 2.4.0: Structural Variants and Advanced Automation in VSClinical ACMGVarSeq 2.4.0: Structural Variants and Advanced Automation in VSClinical ACMG
VarSeq 2.4.0: Structural Variants and Advanced Automation in VSClinical ACMG
Golden Helix
 
The Wide Spectrum of Next-Generation Sequencing Assays with VarSeq
The Wide Spectrum of Next-Generation Sequencing Assays with VarSeqThe Wide Spectrum of Next-Generation Sequencing Assays with VarSeq
The Wide Spectrum of Next-Generation Sequencing Assays with VarSeq
Golden Helix
 
Prenatal Genetic Screening with VarSeq
Prenatal Genetic Screening with VarSeqPrenatal Genetic Screening with VarSeq
Prenatal Genetic Screening with VarSeq
Golden Helix
 
Automated FASTQ to Reports with VarSeq Suite: A fast, flexible solution
Automated FASTQ to Reports with VarSeq Suite: A fast, flexible solutionAutomated FASTQ to Reports with VarSeq Suite: A fast, flexible solution
Automated FASTQ to Reports with VarSeq Suite: A fast, flexible solution
Golden Helix
 
Maximizing the Benefits of Comprehensive Genomic Testing in Cancer Care with ...
Maximizing the Benefits of Comprehensive Genomic Testing in Cancer Care with ...Maximizing the Benefits of Comprehensive Genomic Testing in Cancer Care with ...
Maximizing the Benefits of Comprehensive Genomic Testing in Cancer Care with ...
Golden Helix
 
A User’s Perspective: Somatic Variant Analysis in VarSeq 2.3.0
A User’s Perspective: Somatic Variant Analysis in VarSeq 2.3.0A User’s Perspective: Somatic Variant Analysis in VarSeq 2.3.0
A User’s Perspective: Somatic Variant Analysis in VarSeq 2.3.0
Golden Helix
 
VarSeq 2.3.0: Supporting the Full Spectrum of Genomic Variation
VarSeq 2.3.0: Supporting the Full Spectrum of Genomic VariationVarSeq 2.3.0: Supporting the Full Spectrum of Genomic Variation
VarSeq 2.3.0: Supporting the Full Spectrum of Genomic Variation
Golden Helix
 
VarSeq 2.3.0: New TSO-500 and Genomic Signature Support in VSClinical AMP
VarSeq 2.3.0: New TSO-500 and Genomic Signature Support in VSClinical AMPVarSeq 2.3.0: New TSO-500 and Genomic Signature Support in VSClinical AMP
VarSeq 2.3.0: New TSO-500 and Genomic Signature Support in VSClinical AMP
Golden Helix
 

More from Golden Helix (20)

Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionIntroducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European Union
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
Introducing VSPGx: Pharmacogenomics Testing in VarSeq
Introducing VSPGx: Pharmacogenomics Testing in VarSeqIntroducing VSPGx: Pharmacogenomics Testing in VarSeq
Introducing VSPGx: Pharmacogenomics Testing in VarSeq
 
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
Analyzing Performance of the Twist Exome with CNV Backbone at Various Probe D...
 
From Panels to Genomes with VarSeq: The Complete Tertiary Platform for Short ...
From Panels to Genomes with VarSeq: The Complete Tertiary Platform for Short ...From Panels to Genomes with VarSeq: The Complete Tertiary Platform for Short ...
From Panels to Genomes with VarSeq: The Complete Tertiary Platform for Short ...
 
Enhance Genomic Research with Polygenic Risk Score Calculations in SVS
Enhance Genomic Research with Polygenic Risk Score Calculations in SVSEnhance Genomic Research with Polygenic Risk Score Calculations in SVS
Enhance Genomic Research with Polygenic Risk Score Calculations in SVS
 
VarSeq 2.5.0: VSClinical AMP Workflow from the User Perspective
VarSeq 2.5.0: VSClinical AMP Workflow from the User PerspectiveVarSeq 2.5.0: VSClinical AMP Workflow from the User Perspective
VarSeq 2.5.0: VSClinical AMP Workflow from the User Perspective
 
VarSeq 2.5.0: Empowering Family Planning through Carrier Screening Analysis
VarSeq 2.5.0: Empowering Family Planning through Carrier Screening AnalysisVarSeq 2.5.0: Empowering Family Planning through Carrier Screening Analysis
VarSeq 2.5.0: Empowering Family Planning through Carrier Screening Analysis
 
Identifying Oncogenic Variants in VarSeq
Identifying Oncogenic Variants in VarSeqIdentifying Oncogenic Variants in VarSeq
Identifying Oncogenic Variants in VarSeq
 
Best Practices for Validating a Next-Gen Sequencing Workflow
Best Practices for Validating a Next-Gen Sequencing WorkflowBest Practices for Validating a Next-Gen Sequencing Workflow
Best Practices for Validating a Next-Gen Sequencing Workflow
 
2023 Innovation Awards Winner, Dr. Muthukumaran
2023 Innovation Awards Winner, Dr. Muthukumaran2023 Innovation Awards Winner, Dr. Muthukumaran
2023 Innovation Awards Winner, Dr. Muthukumaran
 
VarSeq 2.4.0: VSClinical ACMG Workflow from the User Perspective
VarSeq 2.4.0: VSClinical ACMG Workflow from the User PerspectiveVarSeq 2.4.0: VSClinical ACMG Workflow from the User Perspective
VarSeq 2.4.0: VSClinical ACMG Workflow from the User Perspective
 
VarSeq 2.4.0: Structural Variants and Advanced Automation in VSClinical ACMG
VarSeq 2.4.0: Structural Variants and Advanced Automation in VSClinical ACMGVarSeq 2.4.0: Structural Variants and Advanced Automation in VSClinical ACMG
VarSeq 2.4.0: Structural Variants and Advanced Automation in VSClinical ACMG
 
The Wide Spectrum of Next-Generation Sequencing Assays with VarSeq
The Wide Spectrum of Next-Generation Sequencing Assays with VarSeqThe Wide Spectrum of Next-Generation Sequencing Assays with VarSeq
The Wide Spectrum of Next-Generation Sequencing Assays with VarSeq
 
Prenatal Genetic Screening with VarSeq
Prenatal Genetic Screening with VarSeqPrenatal Genetic Screening with VarSeq
Prenatal Genetic Screening with VarSeq
 
Automated FASTQ to Reports with VarSeq Suite: A fast, flexible solution
Automated FASTQ to Reports with VarSeq Suite: A fast, flexible solutionAutomated FASTQ to Reports with VarSeq Suite: A fast, flexible solution
Automated FASTQ to Reports with VarSeq Suite: A fast, flexible solution
 
Maximizing the Benefits of Comprehensive Genomic Testing in Cancer Care with ...
Maximizing the Benefits of Comprehensive Genomic Testing in Cancer Care with ...Maximizing the Benefits of Comprehensive Genomic Testing in Cancer Care with ...
Maximizing the Benefits of Comprehensive Genomic Testing in Cancer Care with ...
 
A User’s Perspective: Somatic Variant Analysis in VarSeq 2.3.0
A User’s Perspective: Somatic Variant Analysis in VarSeq 2.3.0A User’s Perspective: Somatic Variant Analysis in VarSeq 2.3.0
A User’s Perspective: Somatic Variant Analysis in VarSeq 2.3.0
 
VarSeq 2.3.0: Supporting the Full Spectrum of Genomic Variation
VarSeq 2.3.0: Supporting the Full Spectrum of Genomic VariationVarSeq 2.3.0: Supporting the Full Spectrum of Genomic Variation
VarSeq 2.3.0: Supporting the Full Spectrum of Genomic Variation
 
VarSeq 2.3.0: New TSO-500 and Genomic Signature Support in VSClinical AMP
VarSeq 2.3.0: New TSO-500 and Genomic Signature Support in VSClinical AMPVarSeq 2.3.0: New TSO-500 and Genomic Signature Support in VSClinical AMP
VarSeq 2.3.0: New TSO-500 and Genomic Signature Support in VSClinical AMP
 

Recently uploaded

Comprehensive Rainy Season Advisory: Safety and Preparedness Tips.pdf
Comprehensive Rainy Season Advisory: Safety and Preparedness Tips.pdfComprehensive Rainy Season Advisory: Safety and Preparedness Tips.pdf
Comprehensive Rainy Season Advisory: Safety and Preparedness Tips.pdf
Dr Rachana Gujar
 
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
Dr Rachana Gujar
 
NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSONNEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
SHAMIN EABENSON
 
Can Allopathy and Homeopathy Be Used Together in India.pdf
Can Allopathy and Homeopathy Be Used Together in India.pdfCan Allopathy and Homeopathy Be Used Together in India.pdf
Can Allopathy and Homeopathy Be Used Together in India.pdf
Dharma Homoeopathy
 
Can coffee help me lose weight? Yes, 25,422 users in the USA use it for that ...
Can coffee help me lose weight? Yes, 25,422 users in the USA use it for that ...Can coffee help me lose weight? Yes, 25,422 users in the USA use it for that ...
Can coffee help me lose weight? Yes, 25,422 users in the USA use it for that ...
nirahealhty
 
MBC Support Group for Black Women – Insights in Genetic Testing.pdf
MBC Support Group for Black Women – Insights in Genetic Testing.pdfMBC Support Group for Black Women – Insights in Genetic Testing.pdf
MBC Support Group for Black Women – Insights in Genetic Testing.pdf
bkling
 
Bath patient Fundamental of Nursing.pptx
Bath patient Fundamental of Nursing.pptxBath patient Fundamental of Nursing.pptx
Bath patient Fundamental of Nursing.pptx
MianProductions
 
Pediatric Emergency Care for Children | Apollo Hospital
Pediatric Emergency Care for Children | Apollo HospitalPediatric Emergency Care for Children | Apollo Hospital
Pediatric Emergency Care for Children | Apollo Hospital
Apollo 24/7 Adult & Paediatric Emergency Services
 
FACIAL NERVE
FACIAL NERVEFACIAL NERVE
FACIAL NERVE
aditigupta1117
 
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COMHUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
priyabhojwani1200
 
Tips for Pet Care in winters How to take care of pets.
Tips for Pet Care in winters How to take care of pets.Tips for Pet Care in winters How to take care of pets.
Tips for Pet Care in winters How to take care of pets.
Dinesh Chauhan
 
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)
bkling
 
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdfChampions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
eurohealthleaders
 
2024 HIPAA Compliance Training Guide to the Compliance Officers
2024 HIPAA Compliance Training Guide to the Compliance Officers2024 HIPAA Compliance Training Guide to the Compliance Officers
2024 HIPAA Compliance Training Guide to the Compliance Officers
Conference Panel
 
一比一原版(EUR毕业证)鹿特丹伊拉斯姆斯大学毕业证如何办理
一比一原版(EUR毕业证)鹿特丹伊拉斯姆斯大学毕业证如何办理一比一原版(EUR毕业证)鹿特丹伊拉斯姆斯大学毕业证如何办理
一比一原版(EUR毕业证)鹿特丹伊拉斯姆斯大学毕业证如何办理
gjsma0ep
 
DR SHAMIN EABENSON - JOURNAL CLUB - NEEDLE STICK INJURY
DR SHAMIN EABENSON - JOURNAL CLUB - NEEDLE STICK INJURYDR SHAMIN EABENSON - JOURNAL CLUB - NEEDLE STICK INJURY
DR SHAMIN EABENSON - JOURNAL CLUB - NEEDLE STICK INJURY
SHAMIN EABENSON
 
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DR Jag Mohan Prajapati
 
LEAD Innovation Launch_WHO Innovation Initiative.pptx
LEAD Innovation Launch_WHO Innovation Initiative.pptxLEAD Innovation Launch_WHO Innovation Initiative.pptx
LEAD Innovation Launch_WHO Innovation Initiative.pptx
ChetanSharma78255
 
CCSN_June_06 2024_jones. Cancer Rehabpptx
CCSN_June_06 2024_jones. Cancer RehabpptxCCSN_June_06 2024_jones. Cancer Rehabpptx
CCSN_June_06 2024_jones. Cancer Rehabpptx
Canadian Cancer Survivor Network
 
Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...
Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...
Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...
Levi Shapiro
 

Recently uploaded (20)

Comprehensive Rainy Season Advisory: Safety and Preparedness Tips.pdf
Comprehensive Rainy Season Advisory: Safety and Preparedness Tips.pdfComprehensive Rainy Season Advisory: Safety and Preparedness Tips.pdf
Comprehensive Rainy Season Advisory: Safety and Preparedness Tips.pdf
 
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
 
NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSONNEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
 
Can Allopathy and Homeopathy Be Used Together in India.pdf
Can Allopathy and Homeopathy Be Used Together in India.pdfCan Allopathy and Homeopathy Be Used Together in India.pdf
Can Allopathy and Homeopathy Be Used Together in India.pdf
 
Can coffee help me lose weight? Yes, 25,422 users in the USA use it for that ...
Can coffee help me lose weight? Yes, 25,422 users in the USA use it for that ...Can coffee help me lose weight? Yes, 25,422 users in the USA use it for that ...
Can coffee help me lose weight? Yes, 25,422 users in the USA use it for that ...
 
MBC Support Group for Black Women – Insights in Genetic Testing.pdf
MBC Support Group for Black Women – Insights in Genetic Testing.pdfMBC Support Group for Black Women – Insights in Genetic Testing.pdf
MBC Support Group for Black Women – Insights in Genetic Testing.pdf
 
Bath patient Fundamental of Nursing.pptx
Bath patient Fundamental of Nursing.pptxBath patient Fundamental of Nursing.pptx
Bath patient Fundamental of Nursing.pptx
 
Pediatric Emergency Care for Children | Apollo Hospital
Pediatric Emergency Care for Children | Apollo HospitalPediatric Emergency Care for Children | Apollo Hospital
Pediatric Emergency Care for Children | Apollo Hospital
 
FACIAL NERVE
FACIAL NERVEFACIAL NERVE
FACIAL NERVE
 
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COMHUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
 
Tips for Pet Care in winters How to take care of pets.
Tips for Pet Care in winters How to take care of pets.Tips for Pet Care in winters How to take care of pets.
Tips for Pet Care in winters How to take care of pets.
 
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)
 
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdfChampions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
 
2024 HIPAA Compliance Training Guide to the Compliance Officers
2024 HIPAA Compliance Training Guide to the Compliance Officers2024 HIPAA Compliance Training Guide to the Compliance Officers
2024 HIPAA Compliance Training Guide to the Compliance Officers
 
一比一原版(EUR毕业证)鹿特丹伊拉斯姆斯大学毕业证如何办理
一比一原版(EUR毕业证)鹿特丹伊拉斯姆斯大学毕业证如何办理一比一原版(EUR毕业证)鹿特丹伊拉斯姆斯大学毕业证如何办理
一比一原版(EUR毕业证)鹿特丹伊拉斯姆斯大学毕业证如何办理
 
DR SHAMIN EABENSON - JOURNAL CLUB - NEEDLE STICK INJURY
DR SHAMIN EABENSON - JOURNAL CLUB - NEEDLE STICK INJURYDR SHAMIN EABENSON - JOURNAL CLUB - NEEDLE STICK INJURY
DR SHAMIN EABENSON - JOURNAL CLUB - NEEDLE STICK INJURY
 
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
DELIRIUM BY DR JAGMOHAN PRAJAPATI.......
 
LEAD Innovation Launch_WHO Innovation Initiative.pptx
LEAD Innovation Launch_WHO Innovation Initiative.pptxLEAD Innovation Launch_WHO Innovation Initiative.pptx
LEAD Innovation Launch_WHO Innovation Initiative.pptx
 
CCSN_June_06 2024_jones. Cancer Rehabpptx
CCSN_June_06 2024_jones. Cancer RehabpptxCCSN_June_06 2024_jones. Cancer Rehabpptx
CCSN_June_06 2024_jones. Cancer Rehabpptx
 
Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...
Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...
Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...
 

Whole Exome Sequencing at Stanford University

  • 1. M. Reza Sailani, PhD Department of Genetics Stanford University http://snyderlab.stanford.edu/index.html sailani@stanford.edu Genetic Determinants of Rare Diseases
  • 2. • Introduction • Our Current state of research • An overview of two whole exome sequencing studies of mendelian diseases. Case#1: Alopecia and Mental Retardation (APMR) Syndrome Case#2: Pseudorheumatoid Dysplasia • Concluding remarks
  • 3. http://snyderlab.stanford.edu/index.html Current Research: Our laboratory develops and uses a variety of approaches to analyze genomes, other omes, and regulatory networks. We apply these approaches to understand human variation and health.
  • 4. Genetic Determinants Of Rare And Complex Diseases: Type 2 diabetes Familial Tremor Alopecia and Mental Retardation Pseudorheumatoid Dysplasia Isolated Congenital Anosmia Deafness and infertility syndrome Epilepsy Leukodystrophies Intellectual Disability Hydroxyurea treatment responses in beta-thalassemia patients
  • 6. Alopecia And Mental Retardation (APMR) Syndrome • A very rare autosomal recessive condition • Only a few families have been reported; most in the context of consanguinity. • Affected individuals manifest with loss of hair on the scalp, the absence of eyebrows and eyelashes, and variable intellectual disability. • However, there is high genetic heterogeneity in APMR cases as none of the families reported before shared the same aberrant locus associated with the disease. • Linkage analyses in the past have identified three regions that are associated with APMR.
  • 7. 3q26.3-q27.3 (chr3:170,900,000-187,900,000) 17Mbp region Alopecia-mental retardation syndrome 1 (APMR1) Alopecia-mental retardation syndrome candidate regions: Linkage Analyses
  • 8. APMR2, on chromosome 3q26.2-q26.31 chr3:167,600,001-175,700,000 APMR3, Chr18: 18q11.2-q12.2 Alopecia-mental retardation syndrome candidate regions: Linkage Analyses
  • 10. Alopecia And Mental Retardation (APMR) Syndrome
  • 11. These previous studies were based on linkage analyses and were able to identify regions of interest, but no specific causative genes or variants. We employed whole-exome sequencing to identify the underlying genetic variant(s) associated with APMR syndrome in a large consanguineous family. Methods: Capture Kit: Agilent SureSelectXT HumanAllExon V5 Four libraries per one lane of HiSeq2500 Hugeseq and BINA pipeline VarSeq for variant filtering
  • 12. HugeSeq Fastq files VarSeq BWA mapping BAM generation Re-aligned around indels with GATK IndelRealigner. base recalibration by GATK BaseRecalibrator Duplicate removal Local realignment Calling variants by GATK HaplotypeCaller VQSR was used to recalibrate the variantsVCF files Pedigree files Disease model filtering: Autosomal Recessive Autosomal Dominant DeNovo X-linked SNP frequency filtering (1000g,dpSNPs,etc ) Pathogenesity filtering (Non_synanmous/Frameshift) Final list of variants (Snyder lab, Nature Biotech 2012) Variant Calling Pipeline
  • 13. We selected variants with minor allele frequency (MAF) less than 0.01 in public databases: • dbSNP Common 144 (Database of Single Nucleotide Polymorphism, NCBI). • 1000 Genome project phase 3 (http://www.1000genomes.org). • Exome Aggregation Consortium (ExAC). • Exome Variant Server-NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (http://evs.gs.washington.edu/EVS/). VarSeq filtering Steps: As an autosomal recessive mode of inheritance is indicated both by the pattern of segregation of APMR syndrome in this family and in previous reported families, we began by searching for homozygous variants.
  • 16. Variant filtering steps using VarSeq software MAF minor allele frequency. 1 kg, 1000 Genome project phase 3,. EXaC, Exome Aggregation Consortium version 0.3. dbSNP 144, Database of Single Nucleotide Polymorphism, NCBI. NHLBI, Exome Variant Server; NHLBI GO Exome Sequencing Project (ESP) The identified variant (rs201849460) is rare, predicted to be deleterious and falls within exon 7 of AHSG gene. (MAF 0.0008% in EXaC, 0.04% in dbSNP 144; no homozygotes)
  • 18. Runs of Homozygosity and AHSG location on chromosome 3. ROH are long stretches of consecutive homozygous genotypes reflecting segments shared identically by descent (Broman and Weber 1999) and known to harbor mutations for recessive diseases. ROH were estimated by H3M2 algorithm (Magi et al. 2014).
  • 19. AHSG resides within a 17 Mb linkage region previously reported to be associated with APMR (APMR1) 3q26.3-q27.3 (chr3:170,900,000-187,900,000) 17Mbp region Alopecia-mental retardation syndrome 1 (APMR1)
  • 20. The amino acid sequence of AHSG colored according to the conservation scores. p.Arg317His occurs in a predicted functional residue, highly conserved and exposed (generated by ConSurf method).
  • 21. We confirmed the homozygosity of this variant by Sanger sequencing
  • 22. Post-translational modifications (PTMs) are common in AHSG protein The identified variant is predicted to affect the pro-peptide Immune-precipitating AHSG from serum followed by SDS polyacrylamide gel electrophoresis
  • 23. Arg317His disrupts a phosphorylation motif We used MIMP algorithm to evaluate the potential impact of p.Arg317His on this motif. p.Arg317His disrupts this phosphorylation motif, potentially leading to a loss of phosphorylation at p.Thr319.
  • 24. • AHSG as a phosphorylated glycoprotein is a multifunctional extracellular calcium- regulatory protein. • Is an important participant of diverse normal and pathological processes, including production of growth hormone (GH), nerve growth factor (NGF), transforming growth factor II (TGFb). • Promotes primary keratinocyte migration. • Is particularly abundant at sites where basal keratinocytes are reorganizing to form hair follicle placodes. We therefore suggest AHSG gene as a potential Candidate for APMR in this family.
  • 25. WISP3 mutation associated with Pseudorheumatoid Dysplasia Case #2
  • 26. Here we report genetic characterization of a family segregating an uncharacterized from of skeletal dysplasia. The patients were asymptomatic at birth, with normal growth, development and intelligence as well as no facial, joint, and skeletal system deformity. However, the disease started to manifest at four to six years of age in affected individuals and progressively worsened.
  • 27. HugeSeq Fastq files VarSeq BWA mapping BAM generation Re-aligned around indels with GATK IndelRealigner. base recalibration by GATK BaseRecalibrator Duplicate removal Local realignment Calling variants by GATK HaplotypeCaller VQSR was used to recalibrate the variantsVCF files Pedigree files Disease model filtering: Autosomal Recessive Autosomal Dominant DeNovo X-linked SNP frequency filtering (1000g,dpSNPs,etc ) Pathogenesity filtering (Non_synanmous/Frameshift) Final list of variants (Snyder lab, Nature Biotech 2012) Variant Calling Pipeline
  • 28. We selected variants with minor allele frequency (MAF) less than 0.01 in public databases: • dbSNP Common 144 (Database of Single Nucleotide Polymorphism, NCBI), • 1000 Genome project phase 3 (http://www.1000genomes.org), • Exome Aggregation Consortium version (ExAC) • Exome Variant Server-NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (http://evs.gs.washington.edu/EVS/), VarSeq filtering Steps: As an autosomal recessive mode of inheritance is indicated by the pattern of segregation of disease in this family, we began by searching for homozygous variants.
  • 29. MAF minor allele frequency. 1 kg, 1000 Genome project phase 3,. EXaC, Exome Aggregation Consortium version 0.3. dbSNP 144, Database of Single Nucleotide Polymorphism, NCBI. NHLBI, Exome Variant Server; NHLBI GO Exome Sequencing Project (ESP) Our study is the first to report a homozygote loss of function mutation for rs121908901; WISP3;c.210C>A; p.Cys70*. VarSeq filtering Steps:
  • 31. We confirmed the homozygosity of this variant by Sanger sequencing and showed that the variant segregates in the family
  • 32. Loss-of-function mutations in the WISP3 gene has been associated with Progressive pseudorheumatoid dysplasia (PPD) In 1998, linkage studies in consanguineous families segregating PPD (El-Shanti et al, 1998; Fischer, J. et al 1998) mapped the candidate region on a 3-cM interval on chromosome 6q22. One year later, Hurvitz et al 1999 showed that mutations in the WISP3 gene that fall within the linkage region are the strongest candidate to cause this autosomal recessive condition (Hurvitz et al 1999).
  • 33. Progressive pseudorheumatoid dysplasia (PPD): A rare skeletal dysplasia characterized by predominant involvement of articular cartilage with progressive joint stiffness. is an autosomal recessive genetic disease. PPD remains a diagnostic challenge because of the rarity of the disease and the heterogeneity in the phenotypes, as well as having similarities with other disorders. Clinical and radiographic findings in a 13-year-old male PPD patient Nature Genetics 23, 94 - 98 (1999) PPD is caused by Wnt1-inducible signaling protein 3 (WISP3) mutations.
  • 34. WISP3 encodes Wnt1-inducible signaling protein 3, a cysteine-rich, multidomain, secreted protein WISP3:c.210C>A p.Cys70* occurs in IGFBP N-terminal domain The variant identified in this study at p.Cys70* would, if not subjected to nonsense mediated mRNA decay, produce a significantly truncated protein that misses major part of the protein making it unlikely that normal protein function would be retained.
  • 35. Combining our whole exome sequencing data with clinical documentation (familial histories, genetic data, clinical and radiological findings), we have diagnosed the families with Progressive Pseudorheumatoid Dysplasia (PPD). Conclusion: